- Home
- GHRS vs SION Comparison
GHRS vs SION Comparison
Compare GHRS & SION Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GHRS
- SION
- Stock Information
- Founded
- GHRS 2018
- SION 2019
- Country
- GHRS Ireland
- SION United States
- Employees
- GHRS N/A
- SION N/A
- Industry
- GHRS Biotechnology: Pharmaceutical Preparations
- SION
- Sector
- GHRS Health Care
- SION
- Exchange
- GHRS Nasdaq
- SION NYSE
- Market Cap
- GHRS 583.1M
- SION 564.4M
- IPO Year
- GHRS 2021
- SION 2025
- Fundamental
- Price
- GHRS $12.03
- SION $13.69
- Analyst Decision
- GHRS Strong Buy
- SION Strong Buy
- Analyst Count
- GHRS 8
- SION 1
- Target Price
- GHRS $30.63
- SION $32.00
- AVG Volume (30 Days)
- GHRS 149.3K
- SION 143.7K
- Earning Date
- GHRS 05-08-2025
- SION 05-12-2025
- Dividend Yield
- GHRS N/A
- SION N/A
- EPS Growth
- GHRS N/A
- SION N/A
- EPS
- GHRS N/A
- SION N/A
- Revenue
- GHRS N/A
- SION N/A
- Revenue This Year
- GHRS N/A
- SION N/A
- Revenue Next Year
- GHRS N/A
- SION N/A
- P/E Ratio
- GHRS N/A
- SION N/A
- Revenue Growth
- GHRS N/A
- SION N/A
- 52 Week Low
- GHRS $6.00
- SION $7.26
- 52 Week High
- GHRS $20.50
- SION $25.19
- Technical
- Relative Strength Index (RSI)
- GHRS 58.82
- SION N/A
- Support Level
- GHRS $10.66
- SION N/A
- Resistance Level
- GHRS $13.00
- SION N/A
- Average True Range (ATR)
- GHRS 0.96
- SION 0.00
- MACD
- GHRS 0.12
- SION 0.00
- Stochastic Oscillator
- GHRS 67.84
- SION 0.00
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.
About SION SIONNA THERAPEUTICS INC
Sionna Therapeutics Inc is a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein to deliver clinically meaningful benefit to CF patients. CF is a progressive and life-threatening genetic disease caused by inherited mutations in the CFTR gene, which heads to insufficient CFTR function. The Company is managed as one operating segment focused on the research and development of cystic fibrosis therapies.